Northgate Software (NGS) — Senior Unsecured Notes
Executive Summary
Demo purchase of $100M face of Senior Unsecured Notes at 96.0 (cash investment $96.5M): current yield 7.0%, yield to maturity 7.7%. Recommendation: HOLD. Credit score 90/100 (Low risk). Base-case IRR 8.1%, downside 4.9%, severe -2.4%; probability-weighted IRR 5.7% vs a 12% hurdle; weighted P(default) 0%; severe-case valuation recovery 100%. HOLD (do not size yet): Base-case IRR clears hurdle (8.1% vs ≥ 12.0%); Expected-cash-flow IRR (probability-weighted) clears hurdle (5.7% vs ≥ 12.0%); Entry yield meets minimum (7.7% vs ≥ 9.0%).
Investment Thesis
High-quality, low-leverage credit. Debt is well covered in every scenario, but pricing near par leaves little spread for the risk taken; we would own the notes only on a spread-widening event.
The question: Does a 7.7% yield on a rank-3 unsecured claim compensate for 0% probability-weighted default risk and 0% severe-case loss?
Company Overview
Mission-critical workflow software for mid-market logistics operators; ~92% recurring revenue. HQ Austin, TX; Software / Vertical SaaS. FY2025A revenue $820M, EBITDA $254M (31.0% margin); total debt $600M, cash $140M. DEMO DATA
Industry / Market
Vertical SaaS has resilient demand and low capital intensity, but valuations compressed as growth normalized; credit outcomes depend on retention rather than cyclicality.
Historical Financial Performance
| $M | FY2022A | FY2023A | FY2024A | FY2025A |
|---|---|---|---|---|
| Revenue | $610.0M | $680.0M | $750.0M | $820.0M |
| % growth | 11.5% | 10.3% | 9.3% | |
| Direct costs / COGS | $183.0M | $190.4M | $202.5M | $213.2M |
| Gross profit (NOI for real estate) | $427.0M | $489.6M | $547.5M | $606.8M |
| % margin | 70.0% | 72.0% | 73.0% | 74.0% |
| Operating expenses (cash, adjusted) | $262.3M | $292.4M | $322.5M | $352.6M |
| EBITDA (company-adjusted basis) | $164.7M | $197.2M | $225.0M | $254.2M |
| % margin | 27.0% | 29.0% | 30.0% | 31.0% |
| D&A | $30.5M | $34.0M | $37.5M | $41.0M |
| Share-based compensation | $0.0M | $0.0M | $0.0M | $0.0M |
| EBIT | $134.2M | $163.2M | $187.5M | $213.2M |
| Interest expense | $38.4M | $40.7M | $43.0M | $45.2M |
| EBT | $95.8M | $122.5M | $144.5M | $168.0M |
| Taxes | $23.9M | $30.6M | $36.1M | $42.0M |
| Net income (model basis) | $71.8M | $91.9M | $108.4M | $126.0M |
| Capex | $18.3M | $20.4M | $22.5M | $24.6M |
| Working capital & other cash items | $2.5M | $3.5M | $3.5M | $3.5M |
| Free cash flow | $81.5M | $102.0M | $119.9M | $138.9M |
Capital Structure
| Tranche | Rank | Secured | Face value | Rate | Maturity | Mark / price |
|---|---|---|---|---|---|---|
| Revolver | 1 | Yes | $0.0M | S+325bp | 2029-06-30 | — |
| First-Lien Term Loan | 1 | Yes | $450.0M | S+355bp | 2030-03-31 | 99.5 |
| Senior Unsecured Notes | 3 | No | $150.0M | 6.75% | 2031-03-31 | 96.0 |
Total debt $600.0M (2.4x EBITDA); net debt $460.0M; liquidity $240M; loan-to-value through the target tranche 30%.
Credit Analysis
Net leverage 1.8x, EBITDA / interest 5.62x, FCF / debt 23.1%, DSCR 3.8x, liquidity ratio 4.8x. Score components: Leverage 15/15, Coverage 15/15, Liquidity 10/10, Free cash flow 10/10, Maturity risk 10/10, Margin stability 9/10, Revenue stability 8/8, Asset coverage 5/12, Industry risk 8/10. Score change vs FY2024A (same capital structure): 90 → 90 (no material factor change).
Debt Maturity Profile
| Period | Debt due | % of debt | Projected liquidity (Base) | Refinancing requirement |
|---|---|---|---|---|
| FY2029E | $0M | 0% | $968M | — |
| FY2030E | $450M | 75% | $1.2B | — |
| 2031 (beyond horizon) | $150M | 25% | $774M | — |
| Tranche | Matures | Balance at maturity | Cash on hand | Net lev. (test ≤) | Pro-forma coverage (test ≥) | Refi rate | Interest burden after | Result | Resolution |
|---|---|---|---|---|---|---|---|---|---|
| Revolver | FY2029E | $0.0M | $651M | -0.2x (8.5x) | 8.71x (1.20x) | 8.0% | $0.0M | REFINANCING PASS | Repaid from cash |
| First-Lien Term Loan | FY2030E | $427.5M | $864M | -0.7x (8.5x) | 8.98x (1.20x) | 8.0% | $0.0M | REFINANCING PASS | Repaid from cash |
Base Case
Revenue CAGR 9.0%; FY2030E EBITDA $401M (31.8% margin); trough EBITDA $277M; peak net leverage 1.1x; minimum EBITDA / interest 6.13x; cumulative FCF $984M. No payment default modelled. IRR 8.1%, MOIC 1.25x.
Downside Case
Revenue CAGR 0.2%; FY2030E EBITDA $245M (29.6% margin); trough EBITDA $218M; peak net leverage 1.5x; minimum EBITDA / interest 4.31x; cumulative FCF $611M. No payment default modelled. IRR 4.9%, MOIC 1.14x.
Severe Downside
Revenue CAGR -4.4%; FY2030E EBITDA $180M (27.5% margin); trough EBITDA $164M; peak net leverage 2.0x; minimum EBITDA / interest 2.87x; cumulative FCF $393M. No payment default modelled. IRR -2.4%, MOIC 0.94x.
Covenant Analysis
No active covenants.
No active covenants.
Recovery Analysis
If the company defaults, recovery value is $1.6B (going concern) in the severe case → 100% recovery (0% LGD) on the target tranche; downside 100%. Recovery value = MAX(going concern $1.3B, liquidation $137M) + cash, less administrative costs; severe case struck at FY2027E.
| Claim (by seniority) | Rank | Claim | Recovery | Recovery % | Loss | Loss % |
|---|---|---|---|---|---|---|
| Recovery value | $1.6B | |||||
| Less: administrative / DIP costs | ($64.2M) | |||||
| First-Lien Term Loan | 1 | $452.6M | $452.6M | 100.0% | $0.0M | 0.0% |
| Senior Unsecured Notes | 3 | $152.5M | $152.5M | 100.0% | $0.0M | 0.0% |
| Total claims | $605.2M | $605.2M | $0.0M | |||
| Equity (residual) | $936.2M | In the money | ||||
Investment Returns
| Base Case | Downside | Severe Downside | |
|---|---|---|---|
| Face value / purchase price / cash investment | $100M / 96.0 / $96.5M UNDERWRITING ASSUMPTION | ||
| Cash interest + exit/recovery proceeds | $20.3M + $100.0M | $20.3M + $90.0M | $20.3M + $70.0M |
| Capital gain / (loss) vs purchase price | $4.0M | ($6.0M) | ($26.0M) |
| MOIC | 1.25x | 1.14x | 0.94x |
| IRR (hurdle 12%) | 8.1% | 4.9% | -2.4% |
Key Risks
- Unsecured, rank 3: $450M of debt ranks ahead.
- Weakest credit-score factor: Asset coverage (4.9 of 12 points).
- Spread compression leaves little return cushion
- AI-driven pricing pressure on workflow tools
Key Protections
- Severe-case valuation recovery of 100% covers the 96.0 purchase price (principal protected).
- Coverage of 5.62x EBITDA / interest; EBITDA can fall 82% before coverage reaches 1.0x.
- Moderate leverage: net debt / EBITDA 1.8x.
- Liquidity of $240M (40% of total debt).
- Base-case refinancing tests pass for all 2 maturing tranche(s); 2 are repaid from cash.
Catalysts
- Fiscal-year renewal cohort data
- Potential refinancing at tighter spreads
Due Diligence Items
| Item | Status | Priority | Open question |
|---|---|---|---|
| Historical financials tied to filings | In Progress | High | Do model inputs reconcile to audited statements? |
| Quality of earnings / EBITDA add-backs | In Progress | High | How much of adjusted EBITDA is add-backs? |
| Free cash flow conversion | In Progress | High | What is cash conversion after capex and working capital? |
| Competitive position and management | Issue Identified | Medium | Share trend and management track record? |
| Debt documentation review | Not Started | High | Priming / drop-down protections and baskets? |
| Covenant package and definitions | Not Started | High | Covenant EBITDA definition and headroom? |
| Maturity profile and refinancing plan | Not Started | High | Is the refinancing plan credible at current leverage? |
| Collateral and lien perfection | In Progress | Medium | What assets secure the instrument? |
| Litigation and contingent liabilities | In Progress | Medium | Any material claims ahead of creditors? |
Recommendation
HOLD. HOLD (do not size yet): Base-case IRR clears hurdle (8.1% vs ≥ 12.0%); Expected-cash-flow IRR (probability-weighted) clears hurdle (5.7% vs ≥ 12.0%); Entry yield meets minimum (7.7% vs ≥ 9.0%).
| Test | Actual | Required | Weight | |
|---|---|---|---|---|
| ✗ | Base-case IRR clears hurdle | 8.1% | ≥ 12.0% | core |
| ✗ | Expected-cash-flow IRR (probability-weighted) clears hurdle | 5.7% | ≥ 12.0% | core |
| ✓ | Downside IRR stays above floor | 4.9% | ≥ 0.0% | core |
| ✓ | Downside recovery meets minimum (valuation waterfall) | 100.0% | ≥ 60.0% | core |
| ✓ | Base-case refinancing succeeds | PASS | PASS | core |
| ✗ | Entry yield meets minimum | 7.7% | ≥ 9.0% | secondary |
| ✓ | Net leverage within maximum | 1.8x | ≤ 6.0x | secondary |
| ✓ | Covenant headroom (base case, minimum) | n/m | ≥ 15.0% | secondary |
| ✓ | Principal protected in severe case (recovery ≥ price) | 100 vs 96.0 | recovery ≥ price | secondary |
| ✗ | No unresolved high-priority diligence | 6 open | 0 open | secondary |
What would change my mind?
- EBITDA declines more than 82% from FY2025A (coverage < 1.0x) — or more than n/m (first covenant breaks).
- The entry price is above 87.0: the base case no longer earns the 12% hurdle (assumed price 96.0).
- Severe-case recovery returns the purchase price only if the distressed valuation multiple is at least 2.0x EBITDA (the severe case assumes 8.0x); the question is how much cushion we want.
- Collateral / enterprise value falls more than 69% from the base-case valuation: the tranche starts to take losses.
- Market access weakens: base-case pro-forma coverage at refinancing is 8.71x vs the 1.20x test, at an assumed 8.0% refinancing rate — a higher spread or lower EBITDA flips the test.
Sources (3)
| Source | Document | Data type | Period | Accession | Doc date | Retrieved | Class |
|---|---|---|---|---|---|---|---|
| CreditIQ demo dataset | Northgate Software — illustrative financial statements FY2022–FY2025 | Income statement / cash flow | FY2022–FY2025 | — | 2026-03-31 | 2026-03-31 | DEMO DATA |
| CreditIQ demo dataset | Northgate Software — illustrative capital structure & covenants | Debt schedule | As of 2026-03-31 | — | 2026-03-31 | 2026-03-31 | DEMO DATA |
| CreditIQ demo dataset | Illustrative indicative bid marks (% of par) | Market price | 2026-03-31 | — | 2026-03-31 | 2026-03-31 | DEMO DATA |
Generated entirely from the structured model (inputs → analysis → memo): every figure reconciles to the Excel workbook (see Settings → Reconciliation). Hypothetical terms are underwriting assumptions. Not investment advice.